Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from
two poster presentations will be presented on Saturday October 26,
2019 at the 20th Annual Fall Scientific Meeting of the Sexual
Medicine Society of North America (SMSNA).
Moderated Poster
Presentation
The poster entitled “Comparison of
Pharmacokinetic Profiles of Testosterone Therapy Products in
Relation to Diurnal Variation of Serum Testosterone Levels” will be
presented by Alexander Pastuszak, MD, PhD, University of Utah
School of Medicine, Salt Lake City, Utah. The submission was among
a select group of key abstracts awarded the distinction of a
moderated poster presentation.
The goal of the study was to review the
pharmacokinetic (PK) profiles of serum testosterone in different
exogenous testosterone formulations and compare these PK profiles
with daily variations in endogenous serum testosterone levels. A
review of daily testosterone variation studies in adult men was
conducted followed by literature searches and product prescribing
information review of a variety of testosterone therapies. Routes
of administration considered were subcutaneous testosterone
enanthate (XYOSTED®), intramuscular testosterone, topical
testosterone gel, topical testosterone solution, subdermal pellets,
nasal testosterone gel, oral testosterone and the testosterone
buccal system.
Date: Saturday, October 26,
2019 – 1:50 p.m.Session: Moderated Poster Session:
AndrogensSession Time: 1:30 p.m. - 3:00 p.m.
Eastern Time Location: OMNI Nashville Hotel,
Nashville, Tennessee
e-Poster Presentation
The poster entitled “Testosterone Patient
Journey Analysis” will be presented by Irwin Goldstein, MD, San
Diego Sexual Medicine, San Diego, California.
Male hypogonadism is a clinical syndrome
resultant of pathological failure within the
hypothalamic-pituitary-testicular axis that normally produces
physiological required concentrations of testosterone.
Erectile dysfunction, fatigue/lethargy, depressive symptoms, and
decreased energy and libido are common symptoms associated with
decreased testosterone concentrations. Testosterone therapy
is clinically recommended in men with hypogonadism.
An analysis of the hypogonadal patient journey
was conducted to explore the initial symptoms, impact of initial
treatment, and patients’ concerns and current mindset about
testosterone replacement therapy.
Date: Saturday, October 26,
2019 – 10:11 a.m.Session: Androgens – e-Poster
session 10Session Time: 10:05 a.m. – 10:30 a.m.
Eastern Time Location: OMNI Nashville Hotel,
Nashville, Tennessee
About SMSNA
Established in 1994, the Sexual Medicine Society
of North America’s objective has been to promote, encourage, and
support the highest standards of practice, research, education, and
ethics in the study of the anatomy, physiology, pathophysiology,
diagnosis, and treatment of human sexual function and dysfunction.
Further, SMSNA provides a forum for the free exchange and
discussion of new ideas, thoughts, and concepts in sexual medicine.
Consisting of over 700 active members, the organization is composed
of North American surgeons, physicians, mental health
professionals, scientists, residents and medical students all
committed to sexual health. The SMSNA seeks to identify
existing and emerging issues in the field of human sexual function
and dysfunction, provide accurate and credible information to
medical professionals, develop standards and guidelines for SEXUAL
MEDICINE research and practice, and produce educational programs
that bring leading-edge concepts of research, clinical practice,
ethics, and politics to health care professionals interested in
SEXUAL MEDICINE and related matters.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused primarily on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary
products include XYOSTED® (testosterone enanthate) injection,
OTREXUP® (methotrexate) injection for subcutaneous use and
Sumatriptan Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: market acceptance,
adequate reimbursement coverage and commercial success of XYOSTED™
and future revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; market acceptance and future revenue from Makena®
subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; the timing and results of the Company’s or its
partners’ research projects or clinical trials of product
candidates in development including projects with Teva and Pfizer
and our proprietary programs for ATRS-1701 and our
development program for the use of subcutaneous methotrexate for
the treatment of ectopic pregnancy; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; achievement of the 2019
revised revenue guidance; the Company’s ability to meet loan
extension and interest only payment milestones and the ability to
repay the debt obligation to Hercules Capital; successful
completion of the transaction with Ferring International Center,
S.A.; the Company’s ability to obtain financial and other resources
for its research, development, clinical, and commercial activities
and other statements regarding matters that are not historical
facts, and involve predictions. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:
Jack HowarthVice President, Corporate Affairs of
Antares609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024